Abstract
One of the main reasons why most patients with advanced cancer are not curable with the therapies available is the broad heterogeneity of cancer cells, inherently related to their genomic instability that reflects defects of cell cycle checkpoints and DNA mismatch repair (MMR). The present paper reviews todays knowledge of MMR. Microsatellite (DNA repetitive sequences) instability (MSI) used as a surrogate marker of MMR defects was associated with a predisposition to somatic mutations of several genes including those involved in the neoplastic transformation and tumor progression. Lynch syndrome is an autosomal dominant cancer predisposition syndrome caused by germ line mutation in genes involved in MMR such as hMLH1 or hMLH2, or less frequently hMLH6 or hPMS2; it is associated with a high risk of intestinal cancer (CRC) and other tumors including endometrial, stomach, kidney and brain. There is ample preclinical evidence that cells deficient in MMR are resistant to methylating agents and to some antimetabolites, including 5FU, which is the drug used most for the CRC, whereas they are equally sensitive to oxaliplatin and possibly more sensitive to irinotecan. More studies are needed on the importance of MMR for sensitivity to different anticancer regimens and drugs, so this knowledge can guide rational therapy according to the tumor MMR status.
Keywords: Mismatch repair, microsatellite instability, response to therapy, colon cancer, Heterogeneity, Cancer cells, Somatic mutations, Surrogate marker, Neoplastic transformation, Tumor progression, Lynch syndrome, Oxaliplatin, Irinotecan, DNA replication, Tumorigenesis, Tumors, Chromosome instability, Aneuploidy, Heterozygosity, Ataxia-teleangectasia, Nijmegen breakage syndrome, Bloom's syndrome, Fanconi anemia, E. coli MMR, hMutSα, hMutLα, Prokaryotes, Meiosis and mitotic recombination, Immuno-histochemistry, Anticancer agents, Procarbazine, Temozolomide, DNA interfering agents, 4FU-based therapy, Dna-topoisomerase I inhibitors
Current Drug Targets
Title: Genetic Instability Influences Drug Response in Cancer Cells
Volume: 11 Issue: 10
Author(s): G. Damia and M. D'Incalci
Affiliation:
Keywords: Mismatch repair, microsatellite instability, response to therapy, colon cancer, Heterogeneity, Cancer cells, Somatic mutations, Surrogate marker, Neoplastic transformation, Tumor progression, Lynch syndrome, Oxaliplatin, Irinotecan, DNA replication, Tumorigenesis, Tumors, Chromosome instability, Aneuploidy, Heterozygosity, Ataxia-teleangectasia, Nijmegen breakage syndrome, Bloom's syndrome, Fanconi anemia, E. coli MMR, hMutSα, hMutLα, Prokaryotes, Meiosis and mitotic recombination, Immuno-histochemistry, Anticancer agents, Procarbazine, Temozolomide, DNA interfering agents, 4FU-based therapy, Dna-topoisomerase I inhibitors
Abstract: One of the main reasons why most patients with advanced cancer are not curable with the therapies available is the broad heterogeneity of cancer cells, inherently related to their genomic instability that reflects defects of cell cycle checkpoints and DNA mismatch repair (MMR). The present paper reviews todays knowledge of MMR. Microsatellite (DNA repetitive sequences) instability (MSI) used as a surrogate marker of MMR defects was associated with a predisposition to somatic mutations of several genes including those involved in the neoplastic transformation and tumor progression. Lynch syndrome is an autosomal dominant cancer predisposition syndrome caused by germ line mutation in genes involved in MMR such as hMLH1 or hMLH2, or less frequently hMLH6 or hPMS2; it is associated with a high risk of intestinal cancer (CRC) and other tumors including endometrial, stomach, kidney and brain. There is ample preclinical evidence that cells deficient in MMR are resistant to methylating agents and to some antimetabolites, including 5FU, which is the drug used most for the CRC, whereas they are equally sensitive to oxaliplatin and possibly more sensitive to irinotecan. More studies are needed on the importance of MMR for sensitivity to different anticancer regimens and drugs, so this knowledge can guide rational therapy according to the tumor MMR status.
Export Options
About this article
Cite this article as:
Damia G. and D'Incalci M., Genetic Instability Influences Drug Response in Cancer Cells, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011317
DOI https://dx.doi.org/10.2174/1389450111007011317 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Jurisprudence Study of Muslim Rules and Effects of Ovarian Transplants in Women with Infertility; A Review
Current Women`s Health Reviews Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome)
Current Pharmaceutical Design Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Synthesis and Biological Evaluation of Aromatase Inhibitors
Letters in Drug Design & Discovery Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism A Comparison of Self-esteem, Body Image, and Depression in Hysterectomized and Non-hysterectomized Iranian Women: A Comparative Cross-sectional Study
Current Women`s Health Reviews Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry Progesterone Receptor Membrane Component 1 and its Accomplice: Emerging Therapeutic Targets in Lung Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators
Medicinal Chemistry Recent Developments of Steroid Sulfatase Inhibitors as Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry HMGA and Cancer: A Review on Patent Literatures
Recent Patents on Anti-Cancer Drug Discovery Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression
Current Medicinal Chemistry Repurposing some of the Well-known Non-steroid Anti-inflammatory Drugs (NSAIDs) for Cancer Treatment
Current Topics in Medicinal Chemistry Liposomes as siRNA Delivery Vectors
Current Drug Metabolism Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets